Will Controversy Lead Medtronic To Sell Its Spine Business? (Forbes)
Could the controversy over Medtronic's bone-graft product Infuse, assailed in a major medical journal last week, lead the medical device company to ditch it’s entire spine business?
Lawrence Biegelsen, a sell-side analyst at Wells Fargo Securities, makes that suggestion in a note downgrading Medtronic to market perform today. He says that last week’s report by The Spine Journal, which said that surgeons receiving millions of dollars from Medtronic failed to disclose side effects from clinical trials of Infuse, is “...
